Company profile for Camurus

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s...
Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Ideon Science Park. SE-223 70 Lund
Telephone
Telephone
+46 46 286 57 30
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot-302609929.html

PR NEWSWIRE
10 Nov 2025

https://www.prnewswire.com/news-releases/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk-302541276.html

PR NEWSWIRE
28 Aug 2025

https://www.prnewswire.com/news-releases/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu-302495549.html

PR NEWSWIRE
01 Jul 2025

https://www.ema.europa.eu/en/documents/overview/oczyesa-epar-medicine-overview_en.pdf

EMA
30 Jun 2025

https://www.prnewswire.com/news-releases/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients-302484906.html

PR NEWSWIRE
18 Jun 2025

https://www.prnewswire.com/news-releases/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins-302472329.html

PR NEWSWIRE
03 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty